Open AccessReal-World Use of FLT3 Tyrosine Kinase Inhibitors in Patients with Relapsed/Refractory FLT3 mutation-Positive Acute Myeloid Leukemia in the United States
Author(s) -
David L. Grinblatt,
Wei Han,
David Nimke,
Feng Qi,
Loretta Sullivan,
Bhavik J. Pandya
Publication year - 2021
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood-2021-145387
Subject(s) - midostaurin , medicine , sorafenib , myeloid leukemia , oncology , tyrosine kinase inhibitor , population , refractory (planetary science) , cancer , physics , environmental health , astrobiology , hepatocellular carcinoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom